Skip to Content

Seagen Inc Ordinary Shares SGEN

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat Seagen Reports Strong Q4 Results, but Guidance Seems Light; Maintaining Our $138 FVE

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Narrow-moat Seagen reported solid fourth-quarter and full-year results that outperformed our expectations on the top and bottom lines. Notably, the company reached its first year of profitability, bringing full-year revenue to about $2.2 billion, driven by the successful launches of its antibody drug conjugates portfolio as well as Merck’s sizable collaboration payment for ladiratuzumab vedotin and Tukysa. After incorporating management’s lighter-than-expected outlook for 2021, we are maintaining our $138 fair value estimate and narrow moat rating. 

Read Full Analysis

Company Profile

Business Description

Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

21823 - 30th Drive South East, Building 3
Bothell, WA, 98021
T +1 425 527-4000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 2,092